Non Melanoma Skin

There are some opportunities to support treatment for non melanoma skin cancers. Dietary coffee consumption is an example, its frequently associated with slower progression in studies of cancer patient dietary habits and this includes skin cancers. Also from patient records, use of low dose aspirin has been reported to slow basal cell carcinoma progress.

One of the more well known supplements with protective actions is vitamin B3 in its niacinamide , or nicotinamide, form. More clinical trials are needed to deepen the evidence. The use of metformin in diabetics has proven to reduce incidence and progression too, berberine is an alternative to explore.

In squamous cell carcinoma, zinc deficiency is strongly linked with poor prognosis. Zinc and other crucial nutrients are continuously depleted by cancer activity, associated inflammation and drugs so it needs to be supported with sustained supplementation. Also beyond basal cell carcinoma, there is evidence that inflammatory immune system activity , seen in the so called NLR marker, is linked to progression. Well proven and widely available astragalus supplements have evidence of reducing this immune inflammation and may help slow progress in squamous cell or other skin cancers.

The so called Th1/Th2 immune system balance is strongly linked to the progression in skin cancers, and to treatment resistance. Molecular iodine solutions are emerging in this area in breast cancer management, seen boosting Th1 anti tumor activity and helping suppress over active Th2 used in resistance. This has improved results in surgery plus chemotherapy and may support increased responses during immunotherapy (see Supplement Library). For immunotherapy the presence of high sodium levels is now identfied as a key marker for success in other cancers. Also in other cancers, AM treatment programs are substantially more effective that PM/evening sessions

Subscribe to the site for Pathfinder ANALYSIS and helpful GUIDE. Build you personal plan with confidence.

Click the IMAGE to view the library entry

Coffee show surprising risk reducing effects from dietary survey data in many cancers

  • Coffee consumption reduces recurrence risk by 30% in BCC
  • Also found in research on new BCC following earlier skin cancers
  • Similar studies report lower risk of any incidence of BCC

Remarkably, coffee consumption reduced the risk of a second BCC (adjusted HR per increase in three cups per day: 0.70). Although caffeinated and decaffeinated coffee consumers could not be differentiated in the overall population, ~90% of the coffee consumers in RS-I, which accounts for most of the included participants, used caffeinated coffee. Several observational studies investigated the association between coffee intake and BCC development.

Nictotinamide and other B3 vitamins have growing evidence in cancer

  • A 23% reduced recurrence rate for BCC and SCC at 500mg daily
  • Similar studies show much reduced actinic keratosis and new BCC/SCC lesions
  • Additional research shows anti-aging and skin health benefits

The rate of new nonmelanoma skin cancers was lower in the nicotinamide group than in the placebo group (relative difference, 23%), with similar differences in the rates of new basal-cell carcinomas and new squamous-cell carcinomas. There was a trend toward increasing effectiveness of nicotinamide among patients who had had higher numbers of nonmelanoma skin cancers in the preceding 5 years…Oral nicotinamide was safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients

Aspirin has a majority of analysis in its favor including all-cause mortality

  • Aspirin reduces BCC risk by a third to a half
  • Proposed mechanism is COX2 inflammation
  • Low dose aspirin is active against many cancer types

In the first phase of the analysis, the data yielded significant results for the effect of aspirin on BCC development. In the second phase, when controls were matched for age and sex, aspirin use yielded an even stronger preventative role in BCC development. The risk of BCC development being more decreased as a result of aspirin use in the matched study versus the unmatched study shows that age and sex are likely confounders in the first phase of this study and potentially other similar studies as well. This finding might explain the positive or lack of association between aspirin and BCC p...

Berberine evidence in metabolic health may help counter cancers use of lipids and sugars to grow

  • Anti-diabetic drug metformin cuts rates of BCC and SCC incidence
  • Risk reduction half or more, with exception of SCC in african americans
  • Clinical trials needed to establish post diagnosis benefits

Our results indicate a reduced risk of non-melanoma skin cancer following exposure to metformin in individuals diagnosed with both SCC and BCC. Subgroup analyses revealed that metformin exposure was associated with a decreased risk of BCC across all sex and ethnicity groups. Metformin use was also associated with a significantly lower risk of SCC, with univariable and multivariable ORs consistently showing reduced odds. However, metformin exposure was not significantly associated with decreased SCC risk in African American patients.

Bromelain proteolytic enzymes in prescription drug trials here

  • Prescription bromelain based topical agents for BCC
  • High rate of removal in pilot studies, needs scaling up
  • A burn and wound healing drug used “off-label”

The results of these preliminary, proof-of-concept studies suggest that CPEEB may be a safe and effective means to treat SBCC and NBCC when properly appplied in an adequate dose. It may offer a rapid, safe, and dose-dependent effective next-generation treatment alternative to current therapies for BCC. Further research and larger-scale studies will be necessary to fully comprehend, demonstrate, and regulate the potential of CPEEB in the management of low-risk BCC and possibly other KC skin tumors.

Zinc is often depleted with cancer related systemic inflammation

  • Incidence and metastatic progression lowered with high zinc levels
  • Lymph node metastasis risk is doubled with zinc deficiency
  • Interventional trials currently only in pre-clinical setting

 

The relationship between decreased serum Zinc level and development of SCC has been revealed in our study, and sZnd has been proved significantly associated to its aggravation and metastasis. Thus, reduction in serum Zinc status should be considered as an indicator to predict its aggressive progression and poor prognosis in patients with SCC, and it also should be emphasized in making the treatment decisions, ….Zinc supplementation may have a role in the prevention and maybe become an adjuvant therapy to its treatment of SCC.

Astragalus actions include protecting and balancing immune responses often with clear effects reported

  • Immune system related inflammation increased neutrophil-to-lymphocyte ratio
  • Other than basal cell most skin cancers show elevated NLR particularly with progression
  • In cutaneous squamous cell carcinoma studies confirm NLR as a prognostic bio-marker

This systematic review concludes that a higher NLR, a robust indicator of adverse prognosis across the common metastatic cancers including malignant melanoma, is a promising biomarker of tumor aggressiveness in all advanced-stage non-melanoma skin cancers (cSCC, EMPD, MCC, and certain cutaneous sarcomas). A distinct exception, with still inconclusive evidence is CTCL, although there are some data indicating that a higher NLR may predict poorer prognosis in patients with notably earlier stages of MF. Finally, given the promising data concerning the impact of the NLR as a prognosticator of th...

Support us and get our essential pathfinder GUIDE. Impacts Analysis, Usage and doses, EXAMPLE plan and supporting comments

Help grow the community

Join the Pubmedders subscriber base

Get our monthly email newletter – designed so you can give us your opinions, thoughts and feedback…

ALL contributions are invested into growing the site to help others.